Total Payments
$17,790
2019 Payments
$9,945
Companies
3
Transactions
43
Medicare Patients
210
Medicare Billing
$26,044
Payment Breakdown by Category
Consulting$13,273 (74.6%)
Travel$2,423 (13.6%)
Research$1,447 (8.1%)
Food & Beverage$626.21 (3.5%)
Education$21.74 (0.1%)
Other$0.00 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $13,273 | 2 | 74.6% |
| Travel and Lodging | $2,423 | 11 | 13.6% |
| Unspecified | $1,447 | 15 | 8.1% |
| Food and Beverage | $626.21 | 14 | 3.5% |
| Education | $21.74 | 1 | 0.1% |
Payments by Type
General
$16,344
28 transactions
Research
$1,447
15 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $9,120 | 27 | $0 (2019) |
| Merck Sharp & Dohme Corporation | $8,649 | 15 | $0 (2019) |
| Mylan Pharmaceuticals Inc. | $21.74 | 1 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2019 | $9,945 | 28 | Merck Sharp & Dohme Corporation ($8,499) |
| 2018 | $7,845 | 15 | Gilead Sciences, Inc. ($7,673) |
All Payment Transactions
43 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $426.46 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $394.00 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $50.00 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $43.06 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $41.07 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $35.94 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $22.58 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/07/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $15.40 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $156.67 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $98.03 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $48.78 | Research |
| Study: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $39.01 | Research |
| Study: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | ||||||
| 12/06/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $14.63 | Research |
| Study: A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | ||||||
| 12/05/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $30.45 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 12/05/2019 | Gilead Sciences, Inc. | — | — | Cash or cash equivalent | $30.45 | Research |
| Study: A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | ||||||
| 04/26/2019 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Consulting Fee | Cash or cash equivalent | $6,800.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 04/26/2019 | Merck Sharp & Dohme Corporation | MK-8591A (Drug) | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/20/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $122.56 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/20/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $37.62 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/20/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $26.87 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/19/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Travel and Lodging | In-kind items and services | $193.72 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/19/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $93.14 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/19/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $64.49 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/19/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $53.74 | General |
| Category: INFECTIOUS DISEASE | ||||||
| 03/19/2019 | Merck Sharp & Dohme Corporation | MK-8591 (Drug) | Food and Beverage | In-kind items and services | $40.30 | General |
| Category: INFECTIOUS DISEASE | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 2 Randomized, Open Label, Active Controlled Study Evaluating the Safety and Efficacy of Long-acting Capsid Inhibitor GS-6207 in Combination with Other Antiretroviral Agents in People Living with HIV | Gilead Sciences, Inc. | $1,344 | 12 |
| A Phase 2/3 Study to Evaluate the Safety and Efficacy of Long Acting Capsid Inhibitor GS 6207 in Combination with an Optimized Background Regimen in Heavily Treatment Experienced People Living with HIV-1 Infection with Multidrug Resistance | Gilead Sciences, Inc. | $102.42 | 3 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 3 | 51 | 63 | $18,718 | $6,317 |
| 2022 | 3 | 62 | 84 | $22,574 | $7,731 |
| 2021 | 3 | 50 | 69 | $20,955 | $6,985 |
| 2020 | 3 | 47 | 62 | $16,343 | $5,010 |
Total Patients
210
Total Services
278
Medicare Billing
$26,044
Procedure Codes
12
All Medicare Procedures & Services
12 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 23 | 23 | $10,534 | $3,068 | 29.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 17 | 22 | $5,214 | $2,105 | 40.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 11 | 18 | $2,970 | $1,145 | 38.5% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 25 | 25 | $11,550 | $4,023 | 34.8% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 25 | 42 | $6,963 | $2,379 | 34.2% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 12 | 17 | $4,061 | $1,329 | 32.7% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 21 | 22 | $10,424 | $3,619 | 34.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 11 | 19 | $5,757 | $1,713 | 29.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 18 | 28 | $4,774 | $1,653 | 34.6% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2020 | 13 | 13 | $6,201 | $2,182 | 35.2% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 23 | 32 | $5,504 | $1,799 | 32.7% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 11 | 17 | $4,638 | $1,029 | 22.2% |
About Dr. Karen Tashima, MD
Dr. Karen Tashima, MD is a Internal Medicine healthcare provider based in Providence, Rhode Island. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/15/2005. The National Provider Identifier (NPI) number assigned to this provider is 1396740551.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Karen Tashima, MD has received a total of $17,790 in payments from pharmaceutical and medical device companies, with $9,945 received in 2019. These payments were reported across 43 transactions from 3 companies. The most common payment nature is "Consulting Fee" ($13,273).
As a Medicare-enrolled provider, Tashima has provided services to 210 Medicare beneficiaries, totaling 278 services with total Medicare billing of $26,044. Data is available for 4 years (2020–2023), covering 12 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Infectious Disease
- Location Providence, RI
- Active Since 06/15/2005
- Last Updated 11/27/2019
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1396740551
Products in Payments
- MK-8591A (Drug) $6,950
- MK-8591 (Drug) $1,549
- Symfi Lo (Drug) $21.74
- ISENTRESS (Drug) $13.24
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Providence
Randall Ingham, M.d, M.D
Internal Medicine — Payments: $154,470
Internal Medicine $154,470
Farah Moustafa, Md, MD
Internal Medicine — Payments: $50,984
Internal Medicine $50,984
Monica Dhakar, M.d, M.D
Internal Medicine — Payments: $47,405
Internal Medicine $47,405
Hajra Awwab, Md, MD
Internal Medicine — Payments: $41,418
Internal Medicine $41,418
Richard Ruggieri, M.d, M.D
Internal Medicine — Payments: $36,352
Internal Medicine $36,352
Dr. Peter Barth, M.d, M.D
Internal Medicine — Payments: $29,192
Internal Medicine $29,192